查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081972

癌症生物標記市場：按生物標記類型、技術、癌症類型、檢測類型、應用和最終用戶分類－2026-2032年全球市場預測

Cancer Biomarkers Market by Biomarker Type, Technology, Cancer Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症生物標記市場將成長至 724.1 億美元，複合年成長率為 11.09%。

主要市場統計數據
基準年 2025 346.6億美元
預計年份：2026年 381.3億美元
預測年份 2032 724.1億美元
複合年成長率 (%) 11.09%

癌症生物標記是可測量的生物訊號，有助於檢測惡性腫瘤、對腫瘤進行分類、預測治療反應、監測微量殘存疾病，並比傳統方法更早識別復發。全球癌症負擔推動了對癌症生物標記的需求。根據國際癌症研究機構（IARC）發布的《2022年全球癌症展望報告》（GLOBOCAN 2022），全球預計將新增約2,000萬例癌症病例，並有970萬人死於癌症，凸顯了早期診斷、精準腫瘤學和長期疾病監測的必要性。

該領域正從單一分析檢測轉向整合基因組學、蛋白質組學、表觀遺傳學、代謝體學和免疫譜的生物標記。臨床上已確立的例子，例如 EGFR、ALK、HER2、BRCA1/2、PD-L1、MSI-H/dMMR、NTRK 和循環腫瘤 DNA (ctDNA)，正在影響伴隨診斷、標靶治療、基於免疫腫瘤學的治療決策以及固體癌和骨髓惡性腫瘤的價值整體癌症治療。

癌症生物標記領域的變革性變化

次世代定序、液態生物檢體、多重免疫組化、數位病理學和分散式檢體採集等技術正在重新定義癌症生物標記領域。經FDA批准和授權的綜合基因組分析檢測，透過將生物標記結果與標靶治療、非腫瘤適應症、遺傳性癌症風險評估和免疫腫瘤學決策聯繫起來，正在加速其臨床應用。

人工智慧對癌症生物標記的累積影響

人工智慧透過大規模分析病理影像、放射影像資料、多體學資料集和真實臨床記錄，加速了癌症生物標記的發現。諸如「癌症基因組圖譜（TCGA）」等公共資源已對33種癌症的2萬多個原發性癌症樣本及其相應的正常樣本進行了分析，為演算法生物標記研究和分子亞型分類奠定了基礎。

關於癌症生物標記引入的關鍵區域性見解

北美憑藉其活躍的癌症研發、廣泛應用的先進診斷技術、FDA對伴隨主導積極主動的核准流程以及龐大的臨床試驗網路，仍然是癌症生物標記領域的領先地區。美國和加拿大受益於成熟的分子病理學能力、國家級癌症研究基礎設施以及液態生物檢體和綜合基因組分析在癌症治療中日益廣泛的應用。在歐洲，強大的學術腫瘤中心、符合EMA標準的精準醫療框架、「歐洲健康數據空間」計畫以及跨境研究舉措都是優勢，但報銷體系、檢查室認證和數據管治的差異仍然影響著各國技術的採用。

癌症生物標記成長的關鍵群體分析

在區域集團內部，七國集團（G7）憑藉著成熟的監管機構、充足的研究經費、先進的癌症治療報銷機制以及完善的臨床試驗基礎設施，引領著高價值癌症生物標記的創新。歐盟則透過體外醫療設備法規、癌症防治資金、跨境資料舉措以及品質標準，推動監管協調，從而創造對經驗證的檢測方法和檢驗臨床應用的需求。北約成員國（其中許多與癌症醫療水平較高的經濟體重疊）日益重視建立穩健的診斷供應鏈、提升檢查室的準備能力以及保障醫療數據安全，將其作為更廣泛的醫療衛生準備工作的一部分。

主要國家癌症生物標記的發展趨勢

美國在伴隨診斷、液態生物檢體的引入、腫瘤臨床試驗、納入臨床指南以及與保險公司就臨床效用價值進行討論方面處於主導地位。加拿大透過省級基因組檢測計畫和癌症相關機構支持精準腫瘤學的發展。同時，墨西哥和巴西正透過公立和私立腫瘤網路擴大服務覆蓋範圍，但仍面臨成本效益、轉診系統和檢查室能力等方面的限制。英國充分利用國家醫療服務體系（NHS）的舉措和集中式檢測途徑，而德國和法國則擁有強大的分子腫瘤學網路和保險報銷機制。義大利和西班牙也在透過當地醫療保健系統擴大癌症生物標記檢測，並日益重視標準化和公平獲取。

為癌症生物標記領域的領導者提供的實用建議

產業領導者應優先考慮經過分析檢驗的檢測方法、具有臨床意義的終點指標以及符合​​監管機構、腫瘤學家、實驗室、病理學家和支付方要求的證據包。診斷和治療公司、醫院、參考實驗室和大學癌症中心之間的夥伴關係對於產生真實世界證據、改善臨床試驗參與者招募以及擴大患者獲得指南推薦的生物標記檢測的機會至關重要。

調查方法

本調查方法建立在整合來自公共衛生、監管、科學和產業等資訊來源的檢驗的二手研究和證據之上。主要參考文獻包括世界衛生組織和國際癌症研究機構的癌症統計數據、美國食品藥物管理局和歐洲藥品管理局的診斷和治療指南、美國國家癌症研究所的資源、同行評審的腫瘤學文獻、臨床試驗註冊資訊、專家指南出版刊物以及公開的監管文件。

結論

隨著醫療保健系統從標準化癌症治療轉向基於分子水平的預防、診斷、治療選擇和後續觀察，癌症生物標記正成為精準腫瘤學的核心。檢驗的檢測方法、液態生物檢體、人工智慧分析、數位病理學、多組體學分析以及真實世界證據的結合，正在不斷提升生物標記主導的癌症治療的臨床價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症生物標記市場：依生物標記類型分類

  • 細胞生物標記
  • 基因生物標記
    • DNA生物標記
    • 表觀遺傳生物標記
    • RNA生物標記
      • 長鏈非編碼RNA
      • 傳訊RNA
      • 微型RNA
  • 代謝生物標記
  • 蛋白質生物標記

第8章 癌症生物標記市場：依技術分類

  • 酵素免疫分析法（ELISA）
  • 流式細胞技術
  • 質譜分析
  • 次世代定序
  • 聚合酵素鏈鎖反應

第9章 癌症生物標記市場：依癌症類型分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 卵巢癌
  • 攝護腺癌

第10章 癌症生物標記市場：依檢測類型分類

  • 液態生物檢體
  • 組織切片檢查

第11章 癌症生物標記市場：依應用領域分類

  • 伴隨診斷
  • 診斷
  • 監測
  • 預測性測試
  • 預後

第12章 癌症生物標記市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 診斷檢查室
  • 醫院
  • 製藥公司

第13章 癌症生物標記市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 癌症生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Burning Rock Biotech Limited
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare Technologies Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Menarini Silicon Biosystems SpA
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Ribomed Biotechnologies, Inc.
  • Siemens Healthineers AG
  • SOPHiA GENETICS SA
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-437517DB6E4D

The Cancer Biomarkers Market is projected to grow by USD 72.41 billion at a CAGR of 11.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.66 billion
Estimated Year [2026] USD 38.13 billion
Forecast Year [2032] USD 72.41 billion
CAGR (%) 11.09%

Cancer biomarkers are measurable biological signals that help detect malignancy, classify tumors, predict treatment response, monitor minimal residual disease, and identify relapse earlier than conventional methods. Demand is anchored in the global cancer burden: IARC's GLOBOCAN 2022 estimated about 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the need for earlier diagnosis, precision oncology, and longitudinal disease monitoring.

The field is moving from single-analyte testing toward integrated genomic, proteomic, epigenetic, metabolomic, and immune-profile biomarkers. Clinically established examples such as EGFR, ALK, HER2, BRCA1/2, PD-L1, MSI-H/dMMR, NTRK, and circulating tumor DNA are shaping companion diagnostics, targeted therapies, immuno-oncology decisions, and value-based cancer care across solid tumors and hematologic malignancies.

Transformative Shifts in the Cancer Biomarkers Landscape

The cancer biomarkers landscape is being reshaped by next-generation sequencing, liquid biopsy, multiplex immunohistochemistry, digital pathology, and decentralized sample collection. FDA-cleared and FDA-approved comprehensive genomic profiling tests have accelerated clinical adoption by linking biomarker results to targeted therapies, tumor-agnostic indications, hereditary cancer risk assessment, and immuno-oncology decisions.

A second shift is the expansion of biomarkers beyond late-stage treatment selection. Screening, early detection, therapy monitoring, and recurrence surveillance are gaining investment as clinicians seek faster, less invasive, and more longitudinal insight into tumor biology. This shift is also increasing demand for standardized pre-analytical workflows, harmonized reporting, external quality assessment, and evidence demonstrating clinical utility in real-world oncology practice.

Cumulative Impact of Artificial Intelligence on Cancer Biomarkers

Artificial intelligence is amplifying cancer biomarker discovery by analyzing pathology images, radiology data, multi-omics datasets, and real-world clinical records at scale. Public resources such as The Cancer Genome Atlas, which profiled more than 20,000 primary cancer and matched normal samples across 33 cancer types, provide a foundation for algorithmic biomarker research and molecular subtype classification.

AI is also improving workflow efficiency in laboratories by supporting variant interpretation, image quantification, quality control, patient stratification, and trial matching. The strongest near-term opportunity is not replacing expert judgment but combining machine learning with validated assays, transparent evidence, bias monitoring, data governance, and regulated clinical decision support that can be audited in routine cancer care.

Key Regional Insights Across Cancer Biomarker Adoption

North America remains a leading region for cancer biomarkers due to high oncology R&D intensity, broad access to advanced diagnostics, active FDA pathways for companion diagnostics, and extensive clinical trial networks. The United States and Canada benefit from established molecular pathology capabilities, national cancer research infrastructure, and growing use of liquid biopsy and comprehensive genomic profiling in oncology care. Europe benefits from strong academic oncology centers, EMA-aligned precision medicine frameworks, the European Health Data Space agenda, and cross-border research initiatives, although reimbursement, laboratory accreditation, and data-governance variation still affect adoption across countries.

Asia-Pacific is the fastest-evolving opportunity as China, Japan, India, South Korea, and Australia expand genomic medicine, oncology screening, national cancer strategies, and local diagnostic manufacturing capacity. Japan and South Korea demonstrate strong regulated adoption of molecular oncology, while China and India are increasing sequencing capacity and cancer diagnostics access for large patient populations. Latin America is improving access through private oncology networks, reference laboratories, and national cancer programs in countries such as Brazil and Mexico, while affordability and uneven specialist access remain constraints. The Middle East is investing in genomic health strategies, cancer centers, and specialty care infrastructure, particularly across Gulf health systems. Africa is gradually building pathology, biobanking, molecular testing, and workforce capacity to address late-stage diagnosis and support equitable cancer biomarker implementation.

Key Group Insights for Cancer Biomarker Growth

Among regional groups, the G7 anchors high-value cancer biomarker innovation through mature regulatory agencies, research funding, advanced oncology reimbursement systems, and deep clinical trial infrastructure. The European Union supports harmonization through the In Vitro Diagnostic Regulation, cancer mission funding, cross-country data initiatives, and quality standards that create demand for validated assays and evidence-based clinical implementation. NATO countries, many of which overlap with advanced oncology economies, increasingly view resilient diagnostic supply chains, laboratory readiness, and health data security as part of broader medical preparedness.

BRICS countries represent scale, epidemiologic diversity, and cost-sensitive innovation, particularly as China and India expand sequencing capacity and Brazil, Russia, and South Africa seek broader oncology diagnostics access under differing health system constraints. ASEAN is advancing cancer diagnostics unevenly across member states, but rising private healthcare investment, medical tourism, and regional reference laboratory models are supporting biomarker testing in urban oncology centers. GCC countries are prioritizing genomics, specialty cancer care, and national precision medicine programs, creating opportunities for molecular testing, companion diagnostics, and AI-enabled oncology workflows within rapidly modernizing health systems.

Key Country Insights in Cancer Biomarkers

The United States leads in companion diagnostics, liquid biopsy adoption, oncology trials, clinical guideline integration, and payer debate over clinical utility. Canada supports precision oncology through provincial genomic testing programs and cancer agencies, while Mexico and Brazil are expanding access through public and private oncology networks but continue to face affordability, referral, and laboratory-capacity constraints. The United Kingdom leverages national health system genomics initiatives and centralized testing pathways, Germany and France maintain strong molecular oncology networks and reimbursement mechanisms, and Italy and Spain are scaling cancer biomarker testing through regional healthcare systems with growing emphasis on standardization and equitable access.

Russia has scientific capability and oncology expertise but faces access, reimbursement, and supply-chain constraints affecting advanced molecular diagnostics. China is rapidly building domestic biomarker platforms, sequencing capacity, and precision oncology programs, while India is growing high-volume molecular diagnostics supported by expanding oncology hospitals and cost-conscious test models. Japan leads in regulated precision medicine adoption, including national approaches to genomic profiling and companion diagnostics. Australia benefits from national genomics programs, strong clinical research networks, and guideline-supported cancer testing, while South Korea combines advanced digital health infrastructure, high screening participation for several cancers, and strong translational cancer research to support biomarker-enabled oncology care.

Actionable Recommendations for Cancer Biomarker Leaders

Industry leaders should prioritize analytically validated assays, clinically meaningful endpoints, and evidence packages that address regulator, oncologist, laboratory, pathologist, and payer requirements. Partnerships among diagnostic developers, therapy developers, hospitals, reference laboratories, and academic cancer centers are essential for generating real-world evidence, improving trial enrollment, and expanding patient access to guideline-recommended biomarker testing.

Organizations should also invest in interoperable data infrastructure, AI governance, biospecimen quality controls, external quality assessment, cybersecurity, and scalable reimbursement strategies. The most defensible positions will combine biomarker science, operational reliability, companion diagnostic expertise, regulatory readiness, and equitable access models across mature and emerging oncology markets.

Research Methodology

Research methodology is built from verified secondary research and evidence synthesis across public health, regulatory, scientific, and industry sources. Core references include WHO and IARC cancer statistics, FDA and EMA diagnostic and therapy guidance, NCI resources, peer-reviewed oncology literature, clinical trial registries, professional guideline publications, and publicly available regulatory documentation.

The methodology emphasizes triangulation across disease burden, regulatory approvals, biomarker utility, technology adoption, reimbursement signals, clinical guideline inclusion, laboratory capacity, and regional healthcare readiness. Insights exclude unsupported market claims and prioritize data-backed trends relevant to cancer biomarker strategy, commercialization, clinical implementation, and precision oncology adoption.

Conclusion

Cancer biomarkers are becoming central to precision oncology as healthcare systems shift from generalized cancer treatment toward molecularly guided prevention, diagnosis, therapy selection, and monitoring. The combination of validated assays, liquid biopsy, AI-enabled analytics, digital pathology, multi-omics profiling, and real-world evidence is expanding the clinical value of biomarker-driven cancer care.

Sustainable advancement will depend on clinical utility, reimbursement clarity, regulatory quality, laboratory standardization, data governance, and equitable access. Organizations that align scientific innovation with practical oncology workflows, evidence generation, and patient-centered implementation will be best positioned to lead the next phase of cancer biomarker adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Biomarkers Market, by Biomarker Type

  • 7.1. Cellular Biomarker
  • 7.2. Genetic Biomarker
    • 7.2.1. DNA Biomarker
    • 7.2.2. Epigenetic Biomarker
    • 7.2.3. RNA Biomarker
      • 7.2.3.1. Long Non-Coding RNA
      • 7.2.3.2. Messenger RNA
      • 7.2.3.3. MicroRNA
  • 7.3. Metabolic Biomarker
  • 7.4. Protein Biomarker

8. Cancer Biomarkers Market, by Technology

  • 8.1. Enzyme Linked Immunosorbent Assay
  • 8.2. Flow Cytometry
  • 8.3. Mass Spectrometry
  • 8.4. Next Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Cancer Biomarkers Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Ovarian Cancer
  • 9.5. Prostate Cancer

10. Cancer Biomarkers Market, by Test Type

  • 10.1. Liquid Biopsy
  • 10.2. Tissue Biopsy

11. Cancer Biomarkers Market, by Application

  • 11.1. Companion Diagnostics
  • 11.2. Diagnostics
  • 11.3. Monitoring
  • 11.4. Predictive Testing
  • 11.5. Prognostics

12. Cancer Biomarkers Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Biotechnology Companies
  • 12.3. Contract Research Organizations
  • 12.4. Diagnostic Laboratories
  • 12.5. Hospitals
  • 12.6. Pharmaceutical Companies

13. Cancer Biomarkers Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cancer Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Agilent Technologies, Inc.
  • 17.3. Amoy Diagnostics Co., Ltd.
  • 17.4. Becton, Dickinson and Company
  • 17.5. BGI Genomics Co., Ltd.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. bioMerieux SA
  • 17.8. Burning Rock Biotech Limited
  • 17.9. Caris Life Sciences, Inc.
  • 17.10. Danaher Corporation
  • 17.11. Exact Sciences Corporation
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Foundation Medicine, Inc.
  • 17.14. GE HealthCare Technologies Inc.
  • 17.15. Genomic Health, Inc.
  • 17.16. Guardant Health, Inc.
  • 17.17. Hologic, Inc.
  • 17.18. HTG Molecular Diagnostics, Inc.
  • 17.19. Illumina, Inc.
  • 17.20. Invitae Corporation
  • 17.21. Luminex Corporation
  • 17.22. Menarini Silicon Biosystems S.p.A.
  • 17.23. Myriad Genetics, Inc.
  • 17.24. NanoString Technologies, Inc.
  • 17.25. Natera, Inc.
  • 17.26. NeoGenomics Laboratories, Inc.
  • 17.27. Opko Health, Inc.
  • 17.28. PerkinElmer, Inc.
  • 17.29. QIAGEN N.V.
  • 17.30. Quest Diagnostics Incorporated
  • 17.31. Ribomed Biotechnologies, Inc.
  • 17.32. Siemens Healthineers AG
  • 17.33. SOPHiA GENETICS SA
  • 17.34. Sysmex Corporation
  • 17.35. Thermo Fisher Scientific Inc.
  • 17.36. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MESSENGER RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MESSENGER RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MESSENGER RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)